VALBIOTIS SA: Valbiotis delivers a first order to its Chinese joint venture and targets a commercial launch in China by the end of 2026
02/11/2026 17:41Informations privilégiéesInformations réglementées continues
AMFPublicación inmediata
Valbiotis delivers a first order to its Chinese joint venture and targets a commercial launch in China by the end of 2026
Valbiotis delivers a first order to its Chinese joint venture and targets a commercial launch in China by the end of 2026
First registrations obtained in Hong Kong and Singapore, paving the way for physical distribution
- Two orders totaling 50,000 units (boxes of 90 capsules) placed by the Chinese joint venture, covering all four solutions in the ValbiotisPRO® range: the first delivered at the end of October and included in second-half 2026 revenue, the second currently in production, with shipment scheduled in the coming weeks;
- First sales to Chinese consumers expected by the end of 2026, via the leading cross-border e-commerce (CBEC) platforms, at a consumer retail price very significantly higher than in France;
- Hong Kong and Singapore: first registrations obtained by the joint venture for three products, with ValbiotisPRO® Foie to follow; physical distribution under consideration, notably in pharmacies, as well as online sales.
La Rochelle, November 2, 2026 (5:40 pm CET) – Valbiotis (FR0013254851 – ALVAL, PEA-PME eligible), a French laboratory specializing in cardiometabolic health, today announces the delivery to its Chinese joint venture, Hangzhou Valbiotis Life Health Technology, of the first ValbiotisPRO® products – clinically tested natural health solutions – specifically adapted to the local market. This milestone is the prerequisite for the first sales to Chinese consumers, expected by the end of 2026, in line with the announced timeline.
China: two first orders and a launch through cross-border e-commerce
The Chinese joint venture, 49% owned by Valbiotis and 51% by its partner Aika, has to date placed two orders with Valbiotis, totaling 50,000 units (boxes of 90 capsules) covering all four solutions in the ValbiotisPRO® range (Cholestérol, Santé métabolique, Cardio-circulation, Foie). The first order was delivered at the end of October, while the second, currently in production, is expected to ship in the coming weeks. For accounting purposes, the first order will be included in Valbiotis’ second-half 2026 revenue; the second will be as well if it ships before December 31, 2026. Valbiotis is the joint venture’s exclusive supplier and invoices it for its products, with the joint venture handling sales to consumers.
Press release
This first delivery will be followed by the online listing of the products, by the joint venture’s Hong Kong subsidiary, on the leading cross-border e-commerce (CBEC) platforms. This channel gives international health and wellness brands easier access to the Chinese market – separate from the traditional distribution channel, which the joint venture will target at a later stage, once the products are registered in China. In China, the world’s largest e-commerce market, cross-border e-commerce plays a key role in providing access to foreign products, particularly in health, beauty and food, and in meeting growing demand for quality and authenticity. It accounts for around 10% of the Chinese dietary supplement market, estimated overall at between €30 and €40 billion depending on the product categories included(1). CBEC, which relies on dedicated platforms such as Tmall Global, JD Worldwide, Kaola and Xiaohongshu (Little Red Book), benefits from a streamlined regulatory, customs and logistics framework, enabling rapid market entry with limited investment(2). ValbiotisPRO® products will enjoy premium positioning there, with a consumer retail price very significantly higher than in France.